Johnson & Johnson

Johnson & Johnson confirms intent not to enforce patents for SIRTURO® (bedaquiline) for the treatment of multidrug-resistant TB in 134 low- and middle-income countries

The decision is intended to assure current and future generic manufacturers that they may manufacture and sell generic versions of SIRTURO® without a concern that the Company will enforce its bedaquiline patents, provided the generic versions of SIRTURO® are of good quality, medically acceptable, and are used only in the 134 low- and middle-income countries.

Read More →

Stop TB Partnership and Johnson & Johnson announce price reduction for bedaquiline

Stop TB Partnership and Johnson & Johnson, with support from USAID and the Global Fund, announce price reduction for bedaquiline for treatment of drug-resistant TB in low- and middle-income countries.

Read More →

Johnson & Johnson expands efforts to help end TB in India

In advance of the 50th Union World Conference on Lung Health, Johnson & Johnson announced the expansion of its TB program in India. Through a series of new collaborations with several multilateral and non-governmental organizations, as well as the Government of India, the company aims to help support the country's efforts to end TB by 2025, as outlined in its National Strategic Plan for TB Elimination.

Read More →

Johnson & Johnson commits $500 million investment over four years to help end the epidemics of HIV and TB

Johnson & Johnson announced it has committed to ensuring more than $500 million dedicated to world class research & development and delivery programs over the next four years to accelerate global efforts to eliminate HIV and TB by 2030.

Read More →

Johnson & Johnson announces 10-year initiative to help end TB, the world’s #1 infectious killer

J&J’s goal is to save an estimated 1.8 million lives and prevent 12 million new TB infections.

Read More →

Johnson & Johnson announces collaboration between Janssen and USAID to expand access to anti-multidrug-resistant tuberculosis (MDR-TB) compound

Memorandum of Understanding signed to address the global health threat of antibiotic-resistant bacteria

Read More →

Johnson & Johnson announces new grant to Harvard Medical School to combat drug-resistant tuberculosis

New collaboration will help address significant global unmet needs in pediatric drug-resistant tuberculosis (DR-TB) treatment and optimize use of existing DR-TB treatments

Read More →

Page 1 of 1 · Total posts: 7